Navigation Links
Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
Date:8/1/2008

ostics with our acquisition of Molecular Profiling, Inc., now called Caris MPI and the key subsidiary of CMDx, at the beginning of the year."

Dr. Poste has published over 350 scientific papers and co-edited 14 books on cancer, drug delivery and health policy. In 2004 he was named "R&D Scientist of the Year" by R&D Magazine and in 2006 he received the Einstein award from the Global Business Leadership Council. He previously served as chairman of the task force on bioterrorism for the U.S. Department of Defense. He serves as a member of the Defense Science Board of the Department of Defense and the Institute of Medicine Board of Global Health.

"I am honored to have the opportunity to work more closely with the distinguished team David has assembled at Caris Dx and Caris MPI," commented Dr. Poste. "I have appreciated the interactions I have experienced with the group in the past two years in forging the union of anatomic pathology and molecular diagnostics. I look forward to influencing and driving the companies' mission to accelerate the delivery of the highest quality personalized medicine into the marketplace to improve patient care and the efficient use of healthcare resources."

About CDX Holdings

CDX Holdings is the parent company of Caris Diagnostics and Caris Molecular Diagnostics, whose principal subsidiary is Caris MPI. Through its subsidiaries, CDX Holdings is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Formed in 1996, the company is headquartered in Irving, Texas, operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites); and Newton, Massachusetts, and provides services to well over 2,000 physicians nationally.

Caris Diagnostics provides world-class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its ind
'/>"/>

SOURCE CDX Holdings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
2. George Butler Joins Bionovos Board of Directors
3. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
4. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
5. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
6. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
9. Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA
10. Bruker Announces Availability of New HUPO World Congress Proteomics Posters on Web Site
11. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2
... 25 Peptimmune, Inc., a privately held biotechnology company, ... the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in ... is a novel peptide copolymer for the treatment of ... The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, ...
... ... - An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases , ... New York, NY/Rockville, MD (Vocus) ... the National Multiple Sclerosis Society,s subsidiary devoted to bridging the gap between research and ...
... JERUSALEM, August 25 Oramed Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ... announced that it is the recipient of the 2009 ... , Oramed Pharmaceuticals is developing ... and vaccines delivered via injection. Oramed,focuses on the treatment ...
Cached Biology Technology:Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 2Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 4Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award 2Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award 3
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... that children smash to stain their cheeks purple-red and that ... be the key to spreading solar power across the globe, ... and Molecular Materials. Nanotech Center scientists have used the ... inexpensive fiber-based solar cells. The dye acts as an absorber, ...
... is available in German . 48 healthy males ... the start of the experiment, the other half a placebo. The ... in the form of a crying child, a girl hugging her ... to express the depth of feeling they experienced for the persons ...
... - Veterinary vision scientists at the University of Pennsylvania have ... class of photoreceptors of the retina called rods, a critical ... by rod degeneration. In this study, the ... to correct a DNA mutation, was not intended to treat ...
Cached Biology News:Purple Pokeberries hold secret to affordable solar power worldwide 2Hormone spray improves male sensitivity 2Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say 2
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: